251 related articles for article (PubMed ID: 16061855)
1. Promoter hypermethylation is the predominant mechanism in hMLH1 and hMSH2 deregulation and is a poor prognostic factor in nonsmoking lung cancer.
Hsu HS; Wen CK; Tang YA; Lin RK; Li WY; Hsu WH; Wang YC
Clin Cancer Res; 2005 Aug; 11(15):5410-6. PubMed ID: 16061855
[TBL] [Abstract][Full Text] [Related]
2. Correlation between insulin-like growth factor-binding protein-3 promoter methylation and prognosis of patients with stage I non-small cell lung cancer.
Chang YS; Wang L; Liu D; Mao L; Hong WK; Khuri FR; Lee HY
Clin Cancer Res; 2002 Dec; 8(12):3669-75. PubMed ID: 12473575
[TBL] [Abstract][Full Text] [Related]
3. Hypermethylation of RASSF1A promoter is associated with the age at starting smoking and a poor prognosis in primary non-small cell lung cancer.
Kim DH; Kim JS; Ji YI; Shim YM; Kim H; Han J; Park J
Cancer Res; 2003 Jul; 63(13):3743-6. PubMed ID: 12839968
[TBL] [Abstract][Full Text] [Related]
4. Long interspersed nuclear element 1 hypomethylation is a marker of poor prognosis in stage IA non-small cell lung cancer.
Saito K; Kawakami K; Matsumoto I; Oda M; Watanabe G; Minamoto T
Clin Cancer Res; 2010 Apr; 16(8):2418-26. PubMed ID: 20371677
[TBL] [Abstract][Full Text] [Related]
5. Value of p16INK4a and RASSF1A promoter hypermethylation in prognosis of patients with resectable non-small cell lung cancer.
Wang J; Lee JJ; Wang L; Liu DD; Lu C; Fan YH; Hong WK; Mao L
Clin Cancer Res; 2004 Sep; 10(18 Pt 1):6119-25. PubMed ID: 15447998
[TBL] [Abstract][Full Text] [Related]
6. Promoter hypermethylation of RASSF1A and RUNX3 genes as an independent prognostic prediction marker in surgically resected non-small cell lung cancers.
Yanagawa N; Tamura G; Oizumi H; Kanauchi N; Endoh M; Sadahiro M; Motoyama T
Lung Cancer; 2007 Oct; 58(1):131-8. PubMed ID: 17606310
[TBL] [Abstract][Full Text] [Related]
7. Hypermethylation of the TSLC1/IGSF4 promoter is associated with tobacco smoking and a poor prognosis in primary nonsmall cell lung carcinoma.
Kikuchi S; Yamada D; Fukami T; Maruyama T; Ito A; Asamura H; Matsuno Y; Onizuka M; Murakami Y
Cancer; 2006 Apr; 106(8):1751-8. PubMed ID: 16534787
[TBL] [Abstract][Full Text] [Related]
8. 5' cytosine-phospho-guanine island methylation is responsible for p14ARF inactivation and inversely correlates with p53 overexpression in resected non-small cell lung cancer.
Hsu HS; Wang YC; Tseng RC; Chang JW; Chen JT; Shih CM; Chen CY; Wang YC
Clin Cancer Res; 2004 Jul; 10(14):4734-41. PubMed ID: 15269146
[TBL] [Abstract][Full Text] [Related]
9. Adenomatous polyposis coli gene promoter hypermethylation in non-small cell lung cancer is associated with survival.
Brabender J; Usadel H; Danenberg KD; Metzger R; Schneider PM; Lord RV; Wickramasinghe K; Lum CE; Park J; Salonga D; Singer J; Sidransky D; Hölscher AH; Meltzer SJ; Danenberg PV
Oncogene; 2001 Jun; 20(27):3528-32. PubMed ID: 11429699
[TBL] [Abstract][Full Text] [Related]
10. Quantitative O(6)-methylguanine DNA methyltransferase methylation analysis in curatively resected non-small cell lung cancer: associations with clinical outcome.
Brabender J; Usadel H; Metzger R; Schneider PM; Park J; Salonga D; Tsao-Wei DD; Groshen S; Lord RV; Takebe N; Schneider S; Hölscher AH; Danenberg KD; Danenberg PV
Clin Cancer Res; 2003 Jan; 9(1):223-7. PubMed ID: 12538473
[TBL] [Abstract][Full Text] [Related]
11. Can aberrant promoter hypermethylation of CpG islands predict the clinical outcome of non-small cell lung cancer after curative resection?
Kim YT; Lee SH; Sung SW; Kim JH
Ann Thorac Surg; 2005 Apr; 79(4):1180-8; discussion 1180-8. PubMed ID: 15797047
[TBL] [Abstract][Full Text] [Related]
12. Hypermethylation of E-cadherin gene is frequent and independent of p16INK4A methylation in non-small cell lung cancer: potential prognostic implication.
Shimamoto T; Ohyashiki JH; Hirano T; Kato H; Ohyashiki K
Oncol Rep; 2004 Aug; 12(2):389-95. PubMed ID: 15254707
[TBL] [Abstract][Full Text] [Related]
13. Hypermethylation of the GATA genes in lung cancer.
Guo M; Akiyama Y; House MG; Hooker CM; Heath E; Gabrielson E; Yang SC; Han Y; Baylin SB; Herman JG; Brock MV
Clin Cancer Res; 2004 Dec; 10(23):7917-24. PubMed ID: 15585625
[TBL] [Abstract][Full Text] [Related]
14. The methylation status and protein expression of CDH1, p16(INK4A), and fragile histidine triad in nonsmall cell lung carcinoma: epigenetic silencing, clinical features, and prognostic significance.
Nakata S; Sugio K; Uramoto H; Oyama T; Hanagiri T; Morita M; Yasumoto K
Cancer; 2006 May; 106(10):2190-9. PubMed ID: 16598757
[TBL] [Abstract][Full Text] [Related]
15. Differential impact of p16 inactivation by promoter methylation in non-small cell lung and colorectal cancer: clinical implications.
González-Quevedo R; García-Aranda C; Morán A; De Juan C; Sánchez-Pernaute A; Torres A; Díaz-Rubio E; Balibrea JL; Benito M; Iniesta P
Int J Oncol; 2004 Feb; 24(2):349-55. PubMed ID: 14719111
[TBL] [Abstract][Full Text] [Related]
16. Aberrant methylation of E-cadherin and H-cadherin genes in nonsmall cell lung cancer and its relation to clinicopathologic features.
Kim DS; Kim MJ; Lee JY; Kim YZ; Kim EJ; Park JY
Cancer; 2007 Dec; 110(12):2785-92. PubMed ID: 17960794
[TBL] [Abstract][Full Text] [Related]
17. Inactivation of hMLH1 and hMSH2 by promoter methylation in primary non-small cell lung tumors and matched sputum samples.
Wang YC; Lu YP; Tseng RC; Lin RK; Chang JW; Chen JT; Shih CM; Chen CY
J Clin Invest; 2003 Mar; 111(6):887-95. PubMed ID: 12639995
[TBL] [Abstract][Full Text] [Related]
18. Promoter-hypermethylation associated defective expression of E-cadherin in primary non-small cell lung cancer.
Wang G; Hu X; Lu C; Su C; Luo S; Luo ZW
Lung Cancer; 2008 Nov; 62(2):162-72. PubMed ID: 18468719
[TBL] [Abstract][Full Text] [Related]
19. p16(INK4A) Hypermethylation detected by fluorescent methylation-specific PCR in plasmas from non-small cell lung cancer.
Bearzatto A; Conte D; Frattini M; Zaffaroni N; Andriani F; Balestra D; Tavecchio L; Daidone MG; Sozzi G
Clin Cancer Res; 2002 Dec; 8(12):3782-7. PubMed ID: 12473590
[TBL] [Abstract][Full Text] [Related]
20. Hypermethylation of FHIT as a prognostic marker in nonsmall cell lung carcinoma.
Maruyama R; Sugio K; Yoshino I; Maehara Y; Gazdar AF
Cancer; 2004 Apr; 100(7):1472-7. PubMed ID: 15042681
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
